Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | F11 | P03951 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30993446 | 1.00 | LPL (0.50) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL3690091 | 0.86 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16105038 | 0.85 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1290153 | 0.85 | LPL (0.51) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4813256 | 0.85 | CA1 (0.45) | LPLLIPGCA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL31547133 | 0.85 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL24252766 | 0.84 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL60127 | 0.84 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL59080 | 0.82 | LPL (0.53) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20887537 | 0.82 | LPL (0.46) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117258127-A | Insulin release controllable microneedle patch with blood glucose concentration response and preparation method thereof | 浙江大学 | 2023-12-22 | — | — | CN | claimed |
| CN-115215855-A | Electron donor-acceptor type fluorescent molecular compound, and preparation method and application thereof | 上海大学 | 2022-10-21 | — | — | CN | claimed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2024-02-29 | — | — | US | disclosed |
| CN-117258127-A | Insulin release controllable microneedle patch with blood glucose concentration response and preparation method thereof | 浙江大学 | 2023-12-22 | — | — | CN | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| WO-2008031594-A1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| EP-1900729-A1 | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors | Novartis AG (CH) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007079164-A2 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079164-A2 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | LPL 1536/4885LIPG 1768/4885CA1 2921/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | LPL 1525/4885LIPG 1712/4885CA1 2909/4885 |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | LPL 4568/4885LIPG 4115/4885CA1 291/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | LPL 3598/4885LIPG 2592/4885CA1 4076/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | LPL 1525/4885LIPG 1712/4885CA1 2909/4885 |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | LPL 1525/4885LIPG 1712/4885CA1 2909/4885 |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | LPL 1698/4885LIPG 712/4885CA1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.